Literature DB >> 3495328

Inhibition of H-ras oncogene transformation of NIH3T3 cells by protease inhibitors.

S J Garte, D D Currie, W Troll.   

Abstract

The protease inhibitors antipain, leupeptin, alpha 1-antitrypsin, and epsilon-aminocaproic acid were found to inhibit transformation of NIH3T3 cells after transfection with an activated H-ras oncogene. Inhibition of focus formation by protease inhibitors was concentration dependent and maximal at 50% of control values. Transfection of a gene for neomycin resistance was not affected by protease inhibitors. Antipain was inactive if present only during the first 2 days of the gene transfer protocol or only during the final 10 days of the experiment. However, the full effect was observed when antipain was added at the subculture step on day 3 and during the subsequent cell proliferation. If cells were not subcultured, the yield of the foci per microgram of DNA was sharply reduced and addition of antipain did not further suppress the transformation rate. Subculture of NIH3T3 cells 3 days after transfection at lower cell densities resulted in higher transformation efficiency. The results suggest that transformation of NIH3T3 cells by a single mutated oncogene may involve multiple stages including cell proliferation and that part of this process is susceptible to inhibition by protease inhibitors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495328

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Effects of retinoic acid on NIH3T3 cell transformation by the H-ras oncogene.

Authors:  L R Cox; J Motz; W Troll; S J Garte
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.

Authors:  Nallasivam Palanisamy; Bushra Ateeq; Shanker Kalyana-Sundaram; Dorothee Pflueger; Kalpana Ramnarayanan; Sunita Shankar; Bo Han; Qi Cao; Xuhong Cao; Khalid Suleman; Chandan Kumar-Sinha; Saravana M Dhanasekaran; Ying-bei Chen; Raquel Esgueva; Samprit Banerjee; Christopher J LaFargue; Javed Siddiqui; Francesca Demichelis; Peter Moeller; Tarek A Bismar; Rainer Kuefer; Douglas R Fullen; Timothy M Johnson; Joel K Greenson; Thomas J Giordano; Patrick Tan; Scott A Tomlins; Sooryanarayana Varambally; Mark A Rubin; Christopher A Maher; Arul M Chinnaiyan
Journal:  Nat Med       Date:  2010-06-06       Impact factor: 53.440

3.  Inhibition of 'in vitro' tumor cell growth by aromatic polyamidines exhibiting antiproteinase activity.

Authors:  C Nastruzzi; G Feriotto; D Spandidos; R Ferroni; M Guarneri; R Barbieri; R Gambari
Journal:  Clin Exp Metastasis       Date:  1989 Jan-Feb       Impact factor: 5.150

4.  Oncogene activation in experimental carcinogenesis: the role of carcinogen and tissue specificity.

Authors:  S J Garte; A E Hochwalt
Journal:  Environ Health Perspect       Date:  1989-05       Impact factor: 9.031

Review 5.  Protease inhibitors interfere with the necessary factors of carcinogenesis.

Authors:  W Troll
Journal:  Environ Health Perspect       Date:  1989-05       Impact factor: 9.031

6.  A serine protease-inhibitory benzamidine derivative inhibits the growth of human colon carcinoma cells.

Authors:  Y Nishimura; W Yasui; K Yoshida; T Matsuyama; K Dohi; E Tahara
Journal:  Jpn J Cancer Res       Date:  1992-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.